Media Inquiries

If you are interested in interviewing a CCR scientist, OR you are a scientist who has been contacted by a member of the media, please contact the NCI Press Office at ncipressofficers@mail.nih.gov or by phone at 240.760.6600.

News and Events

Jim Mitchell in front of a machine and a sign that says X-ray on

Celebrating CCR Careers: James B. Mitchell, Ph.D.

James (Jim) B. Mitchell, Ph.D., is a radiation biologist whose research focuses on evaluation of agents in combination with radiation that either enhance tumor sensitivity or protect normal tissues. After nearly 50 years at the NCI, Mitchell has announced his retirement.

New way to address chemoresistance linked to the protein SLFN11

CCR researchers have discovered two complementary roles for the protein Schlafen-11 (SLFN11) in determining patient response to chemotherapy. These findings have implications for how to overcome this resistance and provide new treatment options for patients with small cell lung cancer (SCLC) and many other cancers.

Genetics, not just smoking, influence small cell lung cancer risk

People with mutations in DNA repair genes may be more likely than others to develop small cell lung cancer. Identifying these mutations in patients could help guide treatment decisions.

DNA damage during a critical phase in the cell cycle called G1

New findings show how damaged cells survive the cell cycle

As cells divide and replicate, important safety checkpoints are in place to ensure that most faulty cells with damaged DNA do not survive the cell cycle. In a new twist, CCR researchers discovered how some damaged cells use molecular inertia to drive past these safety checkpoints and continue through the cell cycle.

New insights into what fuels an aggressive form of kidney disease

Researchers have uncovered a key mechanism behind an aggressive form of kidney cancer, whereby cells lacking an important enzyme are unable to replicate and maintain healthy mitochondrial DNA. This results in more genetic abnormalities in the cells, fueling the growth and spread of cancer.

Clinical trial studies therapy for relapsed/refractory T-cell malignancies

Milos Miljkovic, M.D., M.Sc., Assistant Research Physician in the Lymphoid Malignancies Branch, is leading a study of a 4-drug combination treatment strategy using romidepsin, oral 5-azacitidine, dexamethasone and lenalidomide for T-cell malignancies (TCMs). Researchers are seeking to determine the safety, side effects, and best dose of this 4-drug combination for people with relapsed/refractory TCM.

Study evaluates, treats, and follows patients with gastrointestinal stromal tumors

More than half of all gastrointestinal stromal tumors (GISTs) start in the stomach, but they can start anywhere in the GI tract. Andrew M. Blakely, M.D., Assistant Research Physician in the Surgical Oncology Program, is leading a study of GIST that could benefit current and future patients.

New clinical trial studies immunotherapy combination for metastatic breast cancer

Fatima Karzai, M.D., Associate Research Physician in the Genitourinary Malignancies Branch, is leading a study in adults with breast cancer that has spread to other places in the body. Researchers want to see if a combination of four drugs, which includes immunotherapy, can shrink the tumors of metastatic breast cancer.

Clinical trial studies therapy for adults with BRAF-mutant hairy cell leukemia

Adults with BRAF-mutant hairy cell leukemia, that did not respond to or came back after treatment, may be eligible to participate in a clinical trial at the NIH Clinical Center. Researchers want to see if combining encorafenib and binimetinib has an improved response rate than other drugs previously used to treat HCL.

New connection between gut microbes and liver cancer uncovered in mice

Researchers have uncovered a mechanism by which gut microbes can influence the immune response against nearby liver tumors in mice. The new findings could potentially explain why some people with liver or gut diseases, such as primary sclerosing cholangitis and colitis, tend to be more susceptible to cholangiocarcinoma.

Immunotherapy combination tested for advanced/metastatic solid tumors

Adults with locally advanced or metastatic solid tumors that cannot be treated with surgery may be eligible to participate in a clinical trial at the NIH Clinical Center. James L. Gulley, M.D., Ph.D., Chief of the Genitourinary Malignancies Branch, is leading a study exploring several different combinations of immunotherapies to see if they improve responses in people with cancer.

Breadcrumb

News and Events